Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma (vol 46, pg 107S, 2005)

被引：0
|
作者：
Teunissen
机构：
来源：
JOURNAL OF NUCLEAR MEDICINE | 2005年 / 46卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：822 / 822
页数：1
相关论文
共 10 条
  • [1] Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma
    Teunissen, JJM
    Kwekkeboom, DJ
    Kooij, PPM
    Bakker, WH
    Krenning, EP
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 107S - 114S
  • [2] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campenni, Alfredo
    Pignata, Salvatore A.
    Baldari, Sergio
    [J]. ENDOCRINE, 2015, 50 (02) : 516 - 518
  • [3] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Alfredo Campennì
    Salvatore A. Pignata
    Sergio Baldari
    [J]. Endocrine, 2015, 50 : 516 - 518
  • [4] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Zohreh Maghsoomi
    Zahra Emami
    Ramin Malboosbaf
    Mojtaba Malek
    Mohammad E. Khamseh
    [J]. BMC Cancer, 21
  • [5] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    [J]. BMC CANCER, 2021, 21 (01)
  • [6] Somatostatin Receptor Imaging in Non-131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Low Fraction of Patients Suitable for Peptide Receptor Radionuclide Therapy and Evidence of Chromogranin A Level-Positive Neuroendocrine Differentiation
    Jois, Bhargavi
    Asopa, Ramesh
    Basu, Sandip
    [J]. CLINICAL NUCLEAR MEDICINE, 2014, 39 (06) : 505 - 510
  • [7] RETRACTION: Demographical analysis of the patients received radioiodine therapy for the differentiated thyroid carcinoma in our clinic (Retraction of Vol 18, Pg 27, 2012)
    Elboga, Umut
    Dogan, Nese
    Kalender, Ebuzer
    Celen, Y. Zeki
    Yilmaz, Mustafa
    Demir, Hasan Deniz
    Erkilic, Suna
    Karaoglan, Huseyin
    [J]. EUROPEAN JOURNAL OF THERAPEUTICS, 2014, 20 (04): : 345 - 345
  • [8] Peptide Receptor Radionuclide Therapy of Non-radioiodine AvidorRadioiodine Therapy RefractoryDifferentiated Thyroid Cancer and Medullary Thyroid Cancer using 90Y- and 177Lu-labelled Somatostatin Analogs
    Liu, Qingxing
    Zhang, Jingjing
    Singh, Aviral
    Schuchardt, Christiane
    Kulkarni, Harshad
    Zhu, Zhaohui
    Baum, Richard
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [9] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment (vol 66, pg 269, 2022)
    Mottaghi, Mahdi
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (04): : 587 - 587
  • [10] 141 - Peptide receptor radionuclide therapy for metastatic bronchopulmonary carcinoid tumours: A single ENETS Centre of Excellence experience (vol 127, pg S59, 2019)
    Evans, J.
    Wang, W. M.
    Newsom-Davis, T.
    Sharma, R.
    [J]. LUNG CANCER, 2020, 145 : 227 - 227
1